The phase III SKYSCRAPER-01 did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.Â
